Clinical Trial Info

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents (DNA)

Authored by

This was a multicenter, randomized study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo. In Part A, the primary objective was to evaluate the safety and tolerability of the vaccine in different vaccination regimens. In Part B, the primary objectives were to evaluate the safety and efficacy of the vaccine compared to placebo.


Results for this trial can be seen here.